MS Australia advocates for strategic investments in research, healthcare, disability, and aged care to address the growing personal and economic impact of MS.
MS Australia advocates for strategic investments in research, healthcare, disability, and aged care to address the growing personal and economic impact of MS.
You are invited: Advancing MS Research in Australia
Join us as we celebrate excellence in MS Australia research, announce and display the exciting projects from our most recent MS Research Grant Round, and discuss the need for greater government investment in neurological research.
You are invited: Advancing MS Research in Australia
Join us as we celebrate excellence in MS Australia research, announce and display the exciting projects from our most recent MS Research Grant Round, and discuss the need for greater government investment in neurological research.
Multiple Sclerosis Prevalence and Health Economic Impact in Australia 2025
The report reveals that a record 37,756 Australians are now living with the chronic neurological disease – a 13.3% increase in just three years since 2021.
Multiple Sclerosis Prevalence and Health Economic Impact in Australia 2025
The report reveals that a record 37,756 Australians are now living with the chronic neurological disease – a 13.3% increase in just three years since 2021.
National plan for neurological conditions could save Australia $7 billion a year
MS Australia CEO and Chair of the Neurological Alliance Australia Rohan Greenland presents the Blueprint to Assistant Health Minister the Hon Rebecca White MP
National plan for neurological conditions could save Australia $7 billion a year
MS Australia CEO and Chair of the Neurological Alliance Australia Rohan Greenland presents the Blueprint to Assistant Health Minister the Hon Rebecca White MP
The goal of the EBV in MS Platform is to better understand the role of EBV in the development of MS and in ongoing disease; and the potential to target EBV to prevent or treat MS
The goal of the EBV in MS Platform is to better understand the role of EBV in the development of MS and in ongoing disease; and the potential to target EBV to prevent or treat MS
“PLATYPUS” - PLatform Adaptive Trial for remYelination and neuroProtection in mUltiple Sclerosis - multi-arm, multi-stage (MAMS) clinical trial which will test two repurposed drugs to help people living with progressive MS.
“PLATYPUS” - PLatform Adaptive Trial for remYelination and neuroProtection in mUltiple Sclerosis - multi-arm, multi-stage (MAMS) clinical trial which will test two repurposed drugs to help people living with progressive MS.
Join us for news and views on the latest research, treatments, and advocacy efforts, as well as candid and informative interviews with our community; those living with MS and their families and carers, together with leading clinicians, researchers, and advocates.
Join us for news and views on the latest research, treatments, and advocacy efforts, as well as candid and informative interviews with our community; those living with MS and their families and carers, together with leading clinicians, researchers, and advocates.
New data shows fenebrutinib delays disability progression in primary progressive MS, especially preserving arm function, with a comparable safety profile…
MS Australia’s submission to the inquiry highlights systemic issues in NDIS administration, including inconsistent claims management, inadequate pricing, delayed payments,…
